Deals & Corporate Governance

  • March 05, 2026

    GAO Denies Protest Of $325M CDC Contract

    The U.S. Government Accountability Office denied a protest over the awarding of a $325 million Centers for Disease Control and Prevention contract, finding the agency's extra round of discussions with the winning bidder did not result in an unequal process.

  • March 04, 2026

    Zantac Investor Class Action Time-Barred, Pa. Judge Rules

    The maker of heartburn and acid reflux relief tablet Zantac has defeated a securities fraud class action claiming the company hid for decades the cancer risks associated with the drug, causing a stock price drop when the truth was revealed, after a Pennsylvania federal judge ruled Wednesday that the claims were untimely.

  • March 03, 2026

    Florida Man Pleads Guilty In $24M HIV Drugs Fraud Scheme

    The owner of a marketing company in Florida has pled guilty to receiving kickbacks as part of a $24 million scheme to sign up Medicare and Medicaid beneficiaries for HIV prophylactic medications they did not need.

  • March 03, 2026

    Healthcare REIT Picks Up $64M Senior Housing Portfolio

    Real estate investment trust National Healthcare Properties Inc. has agreed to buy a $64 million collection of senior living communities to capitalize on the country's aging population and limited supply of new housing for retirees, according to an announcement.

  • March 03, 2026

    Fed. Circ. Revives Challenge To Augmented Reality Surgical IP

    The Federal Circuit on Tuesday partly revived a patent challenge brought by a medical technology company, overruling the Patent Trial and Appeal Board in saying that there was no motivation for one to combine the teachings of a prior patent and an informational document.

  • March 03, 2026

    Bankruptcy Expert Details Human Costs Of A Hospital Ch. 11

    Melanie Cyganowski of Otterbourg PC, a former federal bankruptcy judge in New York, talks to Law360 Healthcare Authority about successor liability, regulatory hurdles and some of the hidden costs of hospital bankruptcies.

  • February 27, 2026

    Taxation With Representation: Linklaters, Wilson Sonsini

    In this week's Taxation With Representation, French electric utility Engie acquires UK Power Networks, Gilead Sciences Inc. buys clinical-stage biotechnology company Arcellx Inc., and The Brink's Co. acquires NCR Atleos in a deal that unites two major companies in the ATM business.

  • February 26, 2026

    Justices Told 'Skinny Label' Case Puts Generic Drugs At Risk

    The U.S. government, one named sponsor of the Hatch-Waxman Act, a generic-drug industry group and more have warned the U.S. Supreme Court that a decision that allowed a patent case involving a so-called skinny label to proceed threatens the availability of low-cost generic drugs.

  • February 25, 2026

    9th Circ. Undoes $278M Eli Lilly Payment In Insulin Case

    The Ninth Circuit ruled against a lower court Wednesday in saying pharmaceutical giant Eli Lilly does not owe $278 million in royalties to an Arizona company for insulin-brands sales, saying an agreement between the companies did not cover insulin products Eli Lilly made using a certain yeast expression technology.

  • February 25, 2026

    Novo's $2.1B Vivtex Deal Boosts Obesity Drug Pipeline

    Novo Nordisk said on Wednesday it is partnering with Vivtex Corp. on a deal worth up to $2.1 billion to develop drugs for obesity and related conditions, pressing ahead with a weight loss-drug franchise that has delivered rapid growth alongside regulatory scrutiny and courtroom clashes.

  • February 24, 2026

    8th Circ. Won't Revive Iowa Pathology Lab's Antitrust Claims

    The Eighth Circuit has affirmed a lower court ruling that tossed a case accusing Iowa Pathology Associates of monopolizing pathology services in central Iowa, finding the rival never explained why doctors can't use labs that are located further away.

  • February 23, 2026

    Justices Want Natera's Take On CareDx's False Ad Petition

    The U.S. Supreme Court on Monday asked for Natera's position on a petition from rival CareDx asking the high court to review a Third Circuit decision that erased a $45 million jury award stemming from CareDx's false advertising claims.

  • February 23, 2026

    NJ Watchdog Takes File Fight In Hospital Row To 3rd Circ.

    A New Jersey watchdog will take its bid to shield investigative files from discovery in a hospital's antitrust suit to the Third Circuit, according to a court notice.

  • February 23, 2026

    Ropes, Wilson Sonsini Guide Gilead's $7.8B Arcellx Buy

    Gilead Sciences Inc. announced Monday that it has agreed to acquire clinical-stage biotechnology company Arcellx Inc. for $115 per share in cash plus one contingent value right worth $5 per share, reflecting an implied equity value of $7.8 billion.

  • February 20, 2026

    Taxation With Representation: Freshfields, Simpson Thacher

    In this week's Taxation With Representation, science and technology company Danaher Corp. acquires medical technology company Masimo Corp., Covetrus merges with a unit of fellow animal health technology company Cencora, and private equity firm Leonard Green & Partners LP buys outstanding Mister Car Wash Inc. shares not already owned by LGP affiliates.

  • February 19, 2026

    Justices Urged To Bar Passive Infringement For Skinny Labels

    The Federal Circuit cleared the path for branded-drug makers to claim a rival induced infringement of a patent without taking any active steps to do so, Hikma told the U.S. Supreme Court in a case over so-called skinny labels.

  • February 18, 2026

    NY Judge Trims Umbilical Cord Blood Co. Investor Suit

    A New York federal judge has trimmed a securities class action accusing Global Cord Blood Corp. and others of orchestrating and trying to cover up a scheme in which hundreds of millions of dollars were transferred from Global Cord's cash reserves to its former parent company's founder and other businesses.

  • February 17, 2026

    This Week's Healthcare Earnings: Moderna, Tenet And More

    Healthcare stocks saw big moves in recent days, even as earnings season begins to wind down for the industry.

  • February 13, 2026

    Olympus Slips Whistleblower Suit Over Testing Practices

    A Pennsylvania federal judge has dismissed a whistleblower lawsuit brought by the former head of product development for Olympus Corp. of the Americas, ruling that the ex-executive failed to show he was fired in retaliation for speaking out about what he alleged were company violations of the National Defense Authorization Act.

  • February 13, 2026

    CareDx Seeks High Court Review Of $45M False Ad Case

    Transplant diagnostics company CareDx has asked the U.S. Supreme Court to review a Third Circuit decision that erased a nearly $45 million jury award against rival Natera in a false advertising case, arguing the appeals court is the only one that forbids juries from inferring consumer deception when determining damages.

  • February 11, 2026

    Ventas, Welltower See Growth Amid Senior Housing Push

    Real estate investment trusts Welltower Inc. and Ventas Inc. recorded strong financial results from the last quarter and the full year of 2025, as both companies intensified their focus on senior housing, a sector where they expect to see skyrocketing demand due to demographic trends.

  • February 10, 2026

    Judge Limits Insurers' Exposure in Opioid Coverage Fight

    Insurers garnered several wins Tuesday in a dispute over coverage for thousands of opioid suits against bankrupt pharmaceutical company Endo International, with a Pennsylvania federal court ruling favorably for the carriers on the interpretation of claims-made provisions and the meaning of "damages for bodily injury."

  • February 10, 2026

    This Week's Healthcare Earnings: Lilly, Cigna And More

    About a dozen major healthcare companies have posted year-end results and issued 2026 guidance in recent days, including major names like Eli Lilly, Cigna and CVS. Here's what you need to know from earnings reports this past week.

  • February 09, 2026

    5th Circ. Tosses Challenge To La. 340B Discount Drug Rule

    A Fifth Circuit panel upheld on Monday a Louisiana law that allows the state to stop prescription drug manufacturers from blocking safety-net healthcare providers from contracting with outside pharmacies to dispense discounted medicines under the federal 340B Discount Drug program. 

  • February 09, 2026

    Paul Weiss, Goodwin Steer Eli Lilly's $2.4B Orna Buy

    Pharmaceutical giant Eli Lilly & Co., advised by Paul Weiss Rifkind Wharton & Garrison LLP, on Monday announced that it has agreed to buy Goodwin Procter LLP-led biotechnology firm Orna Therapeutics Inc. in a deal where Orna shareholders could receive up to $2.4 billion in cash.

Expert Analysis

  • How 5 States' Deal Notification Laws Are Guiding Healthcare

    Author Photo

    Healthcare transaction notification laws at various stages of implementation in California, Illinois, Indiana, Oregon and Washington are shaping sector mergers and acquisitions, with significant transparency, continuity of care and compliance implications as providers tackle complex regulatory requirements, says Melesa Freerks at DLA Piper.

  • The Good, The Bad And The Ugly Of Healthcare's PE Boom

    Author Photo

    While an influx of capital may provide access to new resources and innovative technologies, the private equity model's method of funding may be fundamentally at odds with patient-first healthcare, and in recent years that inherent tension has gotten ugly, say Eva Gunasekera and Jaclyn Tayabji at Tycko & Zavareei.

  • High Court Made Profound Mistake In Tossing Purdue Deal

    Author Photo

    The U.S. Supreme Court's recent decision to throw out Purdue Pharma's Chapter 11 plan jeopardizes a multistate agreement that would provide approximately $7 billion in much-needed relief to help fight the opioid epidemic, with states now likely doomed to spend years chasing individual defendants across the globe, says Swain Wood at Morningstar.

  • After Chevron: Scale Tips Favor Away From HHS Agencies

    Author Photo

    The loss of Chevron deference may indirectly aid parties in challenging the U.S. Department of Health and Human Services' interpretations of regulations and could immediately influence several pending cases challenging HHS on technical questions and agency authority, say attorneys at Ropes & Gray.

  • After Chevron: FDA Regulations In The Crosshairs

    Author Photo

    The U.S. Supreme Court's overturning of the Chevron doctrine is likely to unleash an array of challenges against the U.S. Food and Drug Administration, focusing on areas of potential overreach such as the FDA's authority under the Federal Food, Drug and Cosmetic Act, say attorneys at Debevoise.

  • Navigating Scrutiny Of Friendly Professional Corps. In Calif.

    Author Photo

    In light of ongoing scrutiny and challenges to private equity participation in the California healthcare marketplace, particularly surrounding the use of the friendly professional corporation model, management services organizations should consider implementing four best practices, say attorneys at Holland & Knight.

  • Class Actions At The Circuit Courts: June Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy considers two recent decisions from the Third and Tenth Circuits, and identifies practice tips around class action settlements and standing in securities litigation.

  • The Current State Of Healthcare Transaction Reviews In Calif.

    Author Photo

    As of April, certain healthcare transactions in California have been subject to additional notification compliance requirements, and complying with these new rules could significantly delay and discourage some deals, says Andrew Demetriou at Husch Blackwell.

  • Careful Data Governance Is A Must Amid Enforcement Focus

    Author Photo

    Federal and state regulators' heightened focus on privacy enforcement, including the Federal Trade Commission's recent guidance on consumer protection in the car industry, highlight the importance of proactive risk management, compliance and data governance, say Jason Priebe and Danny Riley at Seyfarth.

  • 5 Steps To Navigating State Laws On Healthcare Transactions

    Author Photo

    As more states pass legislation requiring healthcare-transaction notice, private equity investors and other deal parties should evaluate the new laws and consider ways to mitigate their effects, say Carol Loepere and Nicole Aiken-Shaban at Reed Smith.

  • Feds' Biotech Enforcement Efforts Are Too Heavy-Handed

    Author Photo

    The U.S. Department of Justice's recent actions against biotech companies untether the Anti-Kickback Statute from its original legislative purpose, and threaten to stifle innovation and undermine patient quality of care, say attorneys at Ropes & Gray.

  • Del. Ruling Highlights M&A Deal Adviser Conflict Disclosures

    Author Photo

    The Delaware Supreme Court recently reversed the Court of Chancery's dismissal of challenges to Nordic Capital's acquisition of Inovalon, demonstrating the importance of full disclosure of financial adviser conflicts when a going-private merger seeks business judgment rule review, say attorneys at Debevoise.

  • A Recipe For Growth Equity Investing In A Slow M&A Market

    Author Photo

    Carl Marcellino at Ropes & Gray discusses the factors bolstering appetite for growth equity fundraising in a depressed M&A market, and walks through the deal terms and other ingredients that set growth equity transactions apart from bread-and-butter venture capital investing.